Meeting
2023 ASCO Annual Meeting
The impact of high body mass index on hepatocellular carcinoma in viral hepatitis and cirrhosis.
Authors
Moonho Kim
Department of Hematology and Oncology, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, South Korea, Gangneung, South Korea
Moonho Kim , Baek Gyu Jun , Hwang Sik Shin , Sang-Wook Yi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Prevention
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10537)
DOI
10.1200/JCO.2023.41.16_suppl.10537
Abstract #
10537
Poster Bd #
170
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Genomic characterization of HBV-infected hepatocellular carcinoma patients using circulating tumor DNA.
First Author: Daniel Lin
Poster
2014 Gastrointestinal Cancers Symposium
Relationship of ethnicity and overall survival (OS) in Asian patients (pts) on sorafenib for advanced hepatocellular carcinoma (HCC) in British Columbia, Canada.
First Author: Renata D'Alpino Peixoto
Poster
2013 ASCO Annual Meeting
Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis.
First Author: Bruno Sangro
Poster
2012 Gastrointestinal Cancers Symposium
Prevalence of risk factors among patients with hepatocellular carcinoma (HCC) and the general population in an employer group database.
First Author: QuynhChau Diem Doan